DRUG-ELUTING COATINGS ON POLY(DL-LACTIDE)-BASED SCAFFOLDS

摘要

Stents including a poly(D,L-lactide)(PDLLA)-based scaffold and PDLLA based therapeutic layer are disclosed. The PDLLA based scaffold may be amorphous and may include a primer layer. Methods of applying the PDLLA-based coating to the scaffold are disclosed with solvent processing methods using a solvent blend are also disclosed. Methods of removing residual solvent from a PDLLA-base coating that also condition the scaffold are disclosed. Methods of treating restenosis that release drugs to prevent restenosis without interfering with the natural positive remodeling of a vessel are disclosed.

主权项

1. A stent comprising:
a scaffold comprising a poly(D,L-lactide)(PDLLA)-based polymer having at least 50% L-enantiomer and at least 4% D-enantiomer, wherein the polymer is amorphous; and a therapeutic coating disposed over at least a portion of a surface of the scaffold, wherein the therapeutic layer comprises a drug mixed within a coating polymer composed of a poly(D,L-lactide) or poly(D,L-lactide-co-caprolactone).